Screener
Mannkind MNKD Onbody Infusor — Finite Lived Intangible Assets Net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mannkind in its filing.
Tagged under the XBRL concept us-gaap:FiniteLivedIntangibleAssetsNet.
The source filing: Mannkind’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-335054
| Line item | Estimated / Useful Life (Years) | June 30, 2026 / Cost | June 30, 2026 / Accumulated Amortization | June 30, 2026 / Net Book Value | December 31, 2025 / Cost | December 31, 2025 / Accumulated Amortization | December 31, 2025 / Net Book Value |
|---|---|---|---|---|---|---|---|
| Developed technology – on-body infusor | 11.25 | 194,000 | (12,611) | 181,389 | 194,000 | (3,973) | 190,027 |
| ReadyFlow Formulation – IPR&D | — | 129,600 | — | 129,600 | 129,600 | — | 129,600 |
| iSPERSE License – IPR&D(1) | — | 4,300 | — | 4,300 | 4,300 | — | 4,300 |
| Developed technology – V-Go(1) | 7.5 | 1,200 | (524) | 676 | 1,200 | (428) | 772 |
| Total | $329,100 | (13,135) | $315,965 | $329,100 | $(4,401) | $324,699 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Mannkind's onbody infusor — finite lived intangible assets net?
- Mannkind (MNKD) reported onbody infusor — finite lived intangible assets net of $181.39M in Q2 2026.
- What does onbody infusor — finite lived intangible assets net mean?
- This represents the carrying value of the Onbody Infusor segment's finite-lived intangible assets, calculated as the gross cost minus accumulated amortization. It reflects the remaining unamortized value of these assets on the balance sheet. Investors use this to assess the current book value of the segment's intellectual property and technology assets.
Ask your AI about Mannkind's onbody infusor — finite lived intangible assets net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude